These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 26792010)

  • 1. Rethinking on the concept of biomarkers in preclinical Alzheimer's disease.
    Berti V; Polito C; Lombardi G; Ferrari C; Sorbi S; Pupi A
    Neurol Sci; 2016 May; 37(5):663-72. PubMed ID: 26792010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biomarkers in Alzheimer's disease].
    García-Ribas G; López-Sendón Moreno JL; García-Caldentey J
    Rev Neurol; 2014 Apr; 58(7):308-17. PubMed ID: 24677154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Defining and disease-modifying therapy for the preclinical stages of Alzheimer's disease].
    Sakurai H; Hanyu H
    Nihon Rinsho; 2016 Mar; 74(3):438-41. PubMed ID: 27025083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI.
    Wang HF; Tan L; Cao L; Zhu XC; Jiang T; Tan MS; Liu Y; Wang C; Tsai RM; Jia JP; Yu JT;
    J Alzheimers Dis; 2016; 51(1):227-36. PubMed ID: 26836176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy.
    Khan TK; Alkon DL
    J Alzheimers Dis; 2015; 46(4):817-36. PubMed ID: 26402622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease.
    Lista S; Garaci FG; Ewers M; Teipel S; Zetterberg H; Blennow K; Hampel H
    Alzheimers Dement; 2014 May; 10(3):381-92. PubMed ID: 23850330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for preclinical Alzheimer's disease.
    Tan CC; Yu JT; Tan L
    J Alzheimers Dis; 2014; 42(4):1051-69. PubMed ID: 25024325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.
    Spellman DS; Wildsmith KR; Honigberg LA; Tuefferd M; Baker D; Raghavan N; Nairn AC; Croteau P; Schirm M; Allard R; Lamontagne J; Chelsky D; Hoffmann S; Potter WZ; ;
    Proteomics Clin Appl; 2015 Aug; 9(7-8):715-31. PubMed ID: 25676562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
    Thal DR; Attems J; Ewers M
    J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When Does Alzheimer's Disease Really Start? The Role of Biomarkers.
    Lloret A; Esteve D; Lloret MA; Cervera-Ferri A; Lopez B; Nepomuceno M; Monllor P
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease.
    Alexopoulos P; Roesler J; Thierjung N; Werle L; Buck D; Yakushev I; Gleixner L; Kagerbauer S; Ortner M; Grimmer T; Kübler H; Martin J; Laskaris N; Kurz A; Perneczky R
    Eur Arch Psychiatry Clin Neurosci; 2016 Oct; 266(7):587-97. PubMed ID: 26253588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment.
    Hu WT; Chen-Plotkin A; Arnold SE; Grossman M; Clark CM; Shaw LM; Pickering E; Kuhn M; Chen Y; McCluskey L; Elman L; Karlawish J; Hurtig HI; Siderowf A; Lee VM; Soares H; Trojanowski JQ
    Acta Neuropathol; 2010 Jun; 119(6):669-78. PubMed ID: 20232070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty.
    Ruan Q; D'Onofrio G; Sancarlo D; Greco A; Yu Z
    Mol Med Rep; 2016 Oct; 14(4):3184-98. PubMed ID: 27511317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.
    Prvulovic D; Hampel H
    Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker modelling of early molecular changes in Alzheimer's disease.
    Paterson RW; Toombs J; Slattery CF; Schott JM; Zetterberg H
    Mol Diagn Ther; 2014 Apr; 18(2):213-27. PubMed ID: 24281842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Alzheimer's Disease: Implications for Refinement of the Concept.
    Vos SJB; Visser PJ
    J Alzheimers Dis; 2018; 64(s1):S213-S227. PubMed ID: 29865060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.